{"id":"W4379979648","doi":"10.1002/hon.3164_263","title":"An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; Jewish General Hospital","funders":"Gilead Sciences","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Cohort; Internal medicine; Lymphoma; Oncology; Gastroenterology; Cancer; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000210936,0.0005197686,0.002228568,0.0002776353,0.0001135377,0.00003038581,0.0003238481,0.0003616465,0.0000768706],"category_scores_gemma":[0.00007643673,0.0002856331,0.00006925504,0.0006617161,0.000275415,0.0001638087,0.0001811503,0.0001640836,0.0000671879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001332167,"about_ca_system_score_gemma":0.000703732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002038789,"about_ca_topic_score_gemma":0.0003408772,"domain_scores_codex":[0.9964947,0.0004740027,0.0008339258,0.0009912546,0.0005252333,0.0006808778],"domain_scores_gemma":[0.9978718,0.0004105787,0.0003823095,0.0007818686,0.0001711393,0.0003823286],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02354375,0.1812567,0.7489075,0.00005450307,0.0004641185,0.005639321,0.001016923,0.0000158838,0.00004941428,0.0002213379,0.0001790721,0.03865143],"study_design_scores_gemma":[0.2131124,0.1776228,0.6064234,0.0001159686,0.0004374869,0.0002184972,0.000609425,0.0002292745,0.0001738669,0.00001757199,0.0007801476,0.0002592485],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993894,0.000099636,0.000005094852,0.0003321669,0.00007621133,0.004202335,0.00002672192,0.0001558801,0.001207982],"genre_scores_gemma":[0.9976928,0.00009719541,0.0005305519,0.0001733523,0.0000268163,0.001135624,0.0001873915,0.0000526965,0.0001035304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1895686,"threshold_uncertainty_score":0.9999596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05988519933506927,"score_gpt":0.378718182469252,"score_spread":0.3188329831341827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}